Respiratory Failure Clinical Trial
Official title:
High Flow Nasal Cannula Versus Non-invasive Ventilation in Prevention of Escalation to Invasive Mechanical Ventilation in Patients With Acute Hypoxemic Respiratory Failure
Oxygen therapy is first-line treatment in the management of acute respiratory failure (ARF). Different oxygen devices have become available over recent decades, such as low-flow systems (nasal cannula, simple facemask, non-rebreathing reservoir mask) and high-flow systems (Venturi mask) . Since the 90's, non-invasive ventilation (NIV) has been largely used with strong level of evidence in cardiogenic pulmonary edema and chronic obstructive pulmonary disease (COPD) exacerbation. NIV improves gas exchange and reduces inspiratory effort through positive pressure. However, good tolerance to NIV is sometimes difficult to achieve due to frequent leaks around the mask, possibly leading to patient-ventilator asynchrony and even to intubation . High-flow nasal oxygen therapy (HFNO) is an innovative high-flow system that allows for delivering up to 60 liters\ min of heated and fully humidified gas with a FIO2 ranging between 21% and 100% . It is a new method of respiratory support in adults that has been used in neonatal ARF for some years. The reason this study is necessary is because, even though NIV has been demonstrated to prevent endotracheal intubation (and its associated complications) in a broad range of ARF patients, HFNC has been proposed to have the same effect as NIV while being easier tolerated, more physiological , allowing patients to continue to talk, eat and drink through mouth while on HFNC
Oxygen therapy is the first-line treatment in management of acute respiratory failure (ARF).
Different oxygen delivery devices have become available over recent decades, either low-flow
systems (nasal cannula, simple facemask, non-rebreathing reservoir mask) or high-flow systems
(Venturi mask) . The choice of a specific device in management of ARF is based on the
severity of hypoxemia, the underlying mechanisms, the patient's breathing pattern and
tolerance .
Critically ill patients often require high-flow devices to meet their oxygen needs .
Tachypneic patients with ARF, have a peak inspiratory flow rate that is usually high and
often exceeds the oxygen flow delivered by the traditional oxygen devices . Using
conventional devices, oxygen flow is limited to no more than 15 L/min. Meanwhile, the
required inspiratory flow for patients with respiratory failure varies widely in a range from
30 to120 L/min. The difference between patient inspiratory flow and delivered flow is large
with conventional oxygen devices leading to patient discomfort . Moreover; high respiratory
rate can generate significant entrainment of room air in the mask and dilution of the
inspired oxygen with an insufficient oxygen concentration. The suboptimal humidification of
the inhaled oxygen provided by standard bubble humidifiers and the limited and unknown
inspiratory oxygen fraction (FIO2) delivery are additional drawbacks of these devices .
Since the 90's, noninvasive ventilation (NIV) has been largely used with strong level of
evidence in cardiogenic pulmonary edema and chronic obstructive pulmonary disease (COPD)
exacerbation. NIV improves gas exchange and reduces inspiratory effort through positive
pressure. However, good tolerance to NIV is sometimes difficult to achieve due to frequent
leaks around the mask, possibly leading to patient-ventilator asynchrony and even to
intubation. It may have other deleterious effects such as delayed intubation by masking signs
of respiratory distress, or barotrauma by the high tidal volume potentially generated under
positive pressure .
To ensure good results, an appropriate interface is more important than the ventilation mode
. Oronasal masks, nasal masks, and hoods are most commonly used for NIV. Oronasal masks are
usually tried first because they ensure the effects of NIV better than other interfaces.
Unfortunately, it is not comfortable, and many patients find it hard to tolerate. It is also
associated with a relatively high incidence of air leakage. Also, skin lesions at the nose
induced by long-term use of this device may result in frequent treatment interruptions and
discontinuation.
High-flow nasal oxygen therapy (HFNO) is an innovative high-flow system that allows for
delivering up to 60 liters/ min of heated and fully humidified gas with a FIO2 ranging
between 21% and 100% [.
- HFNO delivery systems: main technical characteristics: - The administration of HFNO
requires the following: high pressure sources of oxygen and air, an air-oxygen blender
or a high-flow 'Venturi' system (which permits delivery of an accurate FIO2 between 21%
and 100%), a humidifying and heating system for conditioning the gas to optimal
temperature (37 ºC) and humidity (44mg H2O/ liters), a sterile water reservoir, a
non-condensing circuitry, and an interface . The two most widely marketed HFNO systems
are the Precision Flow by Vapotherm and Optiflow by Fisher & Pykel Healthcare Ltd.
- Physiological effects of HFNC: - Gas from an air/oxygen blender that can generate a
total flow of up to 60 L/min is heated and humidified with an active humidifier and
subsequently delivered through a heated circuit. High flow of adequately heated and
humidified gas is considered to have a number of physiological effects
1. Washout of nasopharyngeal dead space: Washout of upper airway dead space from the
delivery of a large amount of oxygen can improve the efficiency of ventilation and
enhance oxygen delivery . HFNC is the only noninvasive respiratory support that
does not increase dead space. With an oxygen mask, especially at low flow, carbon
dioxide is rebreathed .
2. Warming and humidification of secretions: Warming of inspired oxygen and heating it
to core temperature is more effective at high flow rates (typically >40 L/minute)
than low flow rates. Thus, HFNC is better at heating and humidifying inspired
oxygen than conventional high-flow systems such as Venturi masks or nonrebreathers
(flow rate typically 10 to 15 L/minute) or low-flow systems (flow rates typically
<10 L/minute) . Increased humidification results in increased water content in
mucous, which can facilitate secretion removal and may also decrease the work of
breathing and avoid airway desiccation and epithelial injury
3. Continuous positive airway pressure (CPAP) effect: Several studies in adults have
shown that, similar to infants and neonates, HFNC increases nasopharyngeal airway
pressure that peaks at the end of expiration (ie, "PEEP effect") . This "PEEP
effect" can potentially unload auto-PEEP, decrease work of breathing, and enhance
oxygenation in patients with alveolar filling diseases such as congestive heart
failure or acute respiratory distress syndrome (ARDS). As flow increases,
nasopharyngeal pressure increases (ie, a dose effect) . The CPAP effect is greatest
with the mouth closed. In general, every increase of 10 L/minute of flow yields
approximately 0.7 cm H2O of airway pressure when the mouth is closed and 0.35 cm of
H2O when the mouth is open.
4. Small pliable nasal prongs: HFNC nasal prongs are generally soft and pliable.
Consequently, several studies have reported improved patient comfort with HFNC when
compared with conventional low-flow oxygen delivered through nasal cannula or
high-flow oxygen delivered through a face mask .
5. High flow rates: High flow rates result in minimal entrainment of room air when
HFNC is used; this results in more accurate delivery of oxygen. Patients in
respiratory distress generate high inspiratory flow rates that exceed flow rates of
standard oxygen equipment, resulting in entrainment of room air and a reduction in
the delivery of the set FIO2. The rate of flow in HFNC generally exceeds that of
the patient, entraining very little room air and resulting in an FIO2 that is more
reliably delivered . High flow rates have also been shown to result in an improved
breathing pattern by increasing tidal volume and decreasing respiratory rate .
6. Reduction of work of breathing: The HFNO system may significantly reduce the energy
requirement (metabolic work) associated with gas conditioning. By providing high
gas flows, HFNO reduces the resistance of the upper airway and then decreases the
resistive breathing effort .
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03909854 -
Pragmatic Investigation of Volume Targeted Ventilation-1
|
N/A | |
Recruiting |
NCT03662438 -
HOPE (Home-based Oxygen [Portable] and Exercise) for Patients on Long Term Oxygen Therapy (LTOT)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04030208 -
Evaluating Safety and Efficacy of Umbulizer in Patients Requiring Intermittent Positive Pressure Ventilation
|
N/A | |
Recruiting |
NCT04668313 -
COVID-19 Advanced Respiratory Physiology (CARP) Study
|
||
Recruiting |
NCT04542096 -
Real Time Evaluation of Dynamic Changes of the Lungs During Respiratory Support of VLBW Neonates Using EIT
|
||
Recruiting |
NCT05883137 -
High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
|
||
Completed |
NCT04505592 -
Tenecteplase in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT03943914 -
Early Non-invasive Ventilation and High-flow Nasal Oxygen Therapy for Preventing Delayed Respiratory Failure in Hypoxemic Blunt Chest Trauma Patients.
|
N/A | |
Active, not recruiting |
NCT03472768 -
The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support
|
||
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Not yet recruiting |
NCT02542423 -
Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure.
|
N/A | |
Completed |
NCT02265198 -
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01885442 -
TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01659268 -
Performance of Baccalaureate Nursing Students in Insertion of Laryngeal Mask: a Trial in Mannequins
|
N/A | |
Completed |
NCT01249794 -
Non Invasive Ventilation After Cardiac Surgery
|
N/A | |
Completed |
NCT01204281 -
Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients
|
Phase 4 |